ALBENDAZOLE - Generic Drug Details

What are the generic sources for albendazole and what is the scope of freedom to operate?

Albendazole is the generic ingredient in two branded drugs marketed by Actavis Elizabeth, Alembic, Chartwell Rx, Cipla Ltd, Dr Reddys, Edenbridge Pharms, MSN, Strides Pharma, Zydus Pharms, and Impax Labs Inc, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for albendazole. Seventeen suppliers are listed for this compound.

Summary for ALBENDAZOLE

US Patents:	0
Tradenames:	2
Applicants:	10
NDAs:	10
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	157
Clinical Trials:	119
Patent Applications:	6,015
Drug Prices:	Drug price trends for ALBENDAZOLE
What excipients (inactive ingredients) are in ALBENDAZOLE?	ALBENDAZOLE excipients list
DailyMed Link:	ALBENDAZOLE at DailyMed

See drug prices for ALBENDAZOLE

Recent Clinical Trials for ALBENDAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kintampo Health Research Centre, Ghana	N/A
Public Health Laboratory Ivo de Carneri	Phase 3
National Public Health Institute of Liberia	Phase 2

See all ALBENDAZOLE clinical trials

Pharmacology for ALBENDAZOLE

Drug Class	Anthelmintic
Mechanism of Action	Cytochrome P450 1A Inducers

Medical Subject Heading (MeSH) Categories for ALBENDAZOLE

Anthelmintics

Anticestodal Agents

Antiprotozoal Agents

Tubulin Modulators

Anatomical Therapeutic Chemical (ATC) Classes for ALBENDAZOLE

P02CA	Benzimidazole derivatives
P02C	ANTINEMATODAL AGENTS
P02	ANTHELMINTICS
P	Antiparasitic products, insecticides and repellents

US Patents and Regulatory Information for ALBENDAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Edenbridge Pharms	ALBENDAZOLE	albendazole	TABLET;ORAL	211117-001	May 14, 2019	AB	RX	No	No
Alembic	ALBENDAZOLE	albendazole	TABLET;ORAL	215652-001	Sep 4, 2024	AB	RX	No	No
Chartwell Rx	ALBENDAZOLE	albendazole	TABLET;ORAL	211636-001	Jun 10, 2020		DISCN	No	No
Impax Labs Inc	ALBENZA	albendazole	TABLET;ORAL	020666-001	Jun 11, 1996		DISCN	Yes	No

ALBENDAZOLE Market Analysis and Financial Projection Experimental

Albendazole Market Dynamics and Financial Trajectory

Market Size and Growth Projections

The Albendazole market is poised for significant growth in the coming years. As of 2023, the market was valued at USD 159.1 million, and it is expected to reach USD 171.51 million by 2024. By 2032, the market is projected to grow to USD 312.79 million, reflecting a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period of 2024-2032[1].

Geographical Growth Patterns

The growth of the Albendazole market varies significantly across different regions. The Asia-Pacific region is one of the largest and fastest-growing markets due to the high prevalence of parasitic infections in countries such as India, China, and Southeast Asian nations. Public health campaigns and government initiatives aimed at controlling parasitic diseases have boosted the demand for Albendazole in this region[1].

In North America, the market is driven by the treatment of parasitic infections in both humans and animals. The region's well-established healthcare infrastructure and growing awareness of zoonotic diseases contribute to steady market growth. The veterinary sector, particularly in the U.S. and Canada, also plays a significant role due to the large livestock industries[1].

Drivers of Market Growth

Several key factors are driving the growth of the Albendazole market:

• Increasing Prevalence of Parasitic Infections: The rising cases of parasitic diseases such as soil-transmitted helminths, echinococcosis, and giardiasis, especially in developing regions, are a primary driver. These diseases necessitate widespread use of Albendazole as a first-line treatment[1].
• Governmental Support and Public Health Initiatives: Governments and non-profit organizations are actively involved in promoting access to affordable anti-parasitic drugs, including Albendazole, to reduce the burden of parasitic infections in vulnerable populations[1].
• Expansion of Healthcare Infrastructure: Improving healthcare access, particularly in developing regions, has enabled greater access to anti-parasitic treatments, further boosting market growth[1].

Challenges and Restraints

Despite the optimistic outlook, several challenges could pose barriers to growth:

• Stringent Regulatory Requirements: The regulatory environment, including stringent approval processes for new drugs and compliance requirements for existing Albendazole formulations, poses significant challenges for market participants[1].
• Patent Expirations and Generic Alternatives: The emergence of generic alternatives following patent expirations has led to increased competition. Companies are focusing on strategic collaborations, mergers, and acquisitions to maintain their competitive edge[1].
• Side Effects of Medications: Side effects such as headaches, nausea, bone marrow suppression, and liver inflammation can hamper market growth[4].

Competitive Landscape

The Albendazole market is highly competitive, with several key players employing various strategies to maintain their market share:

• Innovation and Strategic Partnerships: Companies are differentiating themselves through innovation and strategic partnerships. Market consolidation through mergers and acquisitions is a common strategy for enhancing market share and expanding product portfolios[1].
• Organic and Inorganic Growth Strategies: Companies are focusing on organic growth strategies such as product launches and product approvals, as well as inorganic strategies like acquisitions and partnerships[4].

Financial Performance and Investment

The financial trajectory of the Albendazole market is influenced by several financial factors:

• Revenue Growth: The market's revenue is expected to grow significantly, driven by increasing demand and expanding healthcare infrastructure. By 2032, the market is projected to reach USD 312.79 million[1].
• Investment in R&D: Companies are investing heavily in research and development to support late-stage clinical development programs and to address emerging healthcare needs. This investment is crucial for maintaining competitive advantage and capitalizing on new opportunities[2].

Regional Framework and Market Segmentation

The Albendazole market is segmented by region and application:

• Regional Segmentation: The market is analyzed across five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. Each region is further sub-segmented by country and segments[4].
• Application Segmentation: The market is segmented by application, including human and veterinary uses. The veterinary sector, particularly in regions with large livestock industries, is a significant contributor to market growth[1].

PEST and SWOT Analysis

The market dynamics are also influenced by various external and internal factors:

• PEST Analysis: Political, economic, social, and technological factors are evaluated to understand their impact on the Albendazole market in different regions[4].
• SWOT Analysis: Strengths, weaknesses, opportunities, and threats are analyzed to provide a comprehensive understanding of the market's competitive landscape and growth prospects[4].

Key Takeaways

• The Albendazole market is expected to grow significantly, driven by increasing prevalence of parasitic infections and government support.
• The Asia-Pacific region is a key growth area due to high disease prevalence and public health initiatives.
• Companies are focusing on innovation, strategic partnerships, and market consolidation to maintain their competitive edge.
• Regulatory challenges and side effects of medications are potential restraints to market growth.
• Heavy investment in R&D is crucial for addressing emerging healthcare needs and maintaining market share.

Frequently Asked Questions (FAQs)

Q: What is the projected CAGR of the Albendazole market from 2024 to 2032? A: The Albendazole market is expected to grow at a CAGR of 7.8% from 2024 to 2032[1].

Q: Which region is expected to witness the fastest growth in the Albendazole market? A: The Asia-Pacific region is expected to be one of the fastest-growing markets due to the high prevalence of parasitic infections and public health initiatives[1].

Q: What are the primary drivers of the Albendazole market? A: The primary drivers include the increasing prevalence of parasitic infections, governmental support, and the expansion of healthcare infrastructure[1].

Q: What challenges might hinder the growth of the Albendazole market? A: Stringent regulatory requirements, patent expirations, and side effects of medications are potential challenges[1][4].

Q: How are companies in the Albendazole market maintaining their competitive edge? A: Companies are employing strategies such as innovation, strategic partnerships, mergers, and acquisitions to maintain their competitive edge[1][4].

Cited Sources:

1. Global Growth Insights: Albendazole Market Size, Analysis, Trends to 2032
2. GSK: Q3 2024 Results Announcement
3. The Insight Partners: Albendazole Drug Market Insights and Growth by 2031
4. The Insight Partners: Albendazole Market Strategies and Share 2031
5. OpenPR: Albendazole Drug Market Size/Share, Segmentation, Growth